Our findings align with current evidence indicating that lack of D2R expression, previously indicated by decreased mRNA levels, is common in DA-resistant prolactinomas and provides a basis for the discontinuation of DA therapy in D2R negative prolactinomas to avoid possible side effects. The gene discussed is DRD2; the disease is prolactin-producing pituitary gland adenoma.